HARRY C. BOGHIGIAN
`
` 7
`
` Tudor Place 23850 Via Italia Circle Suite 406
`Randolph, NJ 07869-2020 Bonita Springs, Florida 34134
`
`Cell: 973-476-6591 Office: 239 676-7284
`E-Mail: Hcbog@pharmaconsultantsllc.com, PHRMCNSLTNT@aol.co E-Mail: Hcbog@aol.com
`
`Policy level Senior Executive and Chief Operating Officer with extensive experience in general management,
`sales, marketing, direct to consumer advertising, strategic planning and business execution. Demonstrated record
`of accomplishment in exceeding business targets and producing impressive business results. A driving passion for
`delivering incremental value. Strong analytical skills with broad experience in developing and leading high
`performance teams. A creative, high energy, versatile and action oriented business leader providing broad
`perspective, change leadership and desired outcomes.
`
`
`EXPERIENCE
`
`
`
`PBN PHARMA LLC, Chicago, IL
`President
`
`
`PHARMA CONSULTANTS LLC, Randolph, NJ
`President
`
`ROCHE PHARMA, INC., Nutley, NJ
`Vice President, Business Operations
`Vice President, Marketing
`Vice President, Southern Business Operations
`
`HOFFMANN-LA ROCHE, Toronto, Canada
`Sr. Vice President & General Manager, Roche Pharmaceuticals, Canada
`
`HOFFMANN-LA ROCHE, Basel, Switzerland
`Group Director & Global Business Representative
`
`ROCHE LABS, Nutley, NJ
`Product Director
`Regional Sales Director
`Manager, Market Research
`
`HOFFMANN-LA ROCHE, Nutley, NJ
`Division Sales Manager, FL
`Sales Representative, MA, NH, ME
`
`
`
`
`
`
`
`
`
`
`
`
` 2003-
`
`
`
` 2001-
`
`1995-2001
`
`1991-1994
`
`1989-1991
`
`1984-1989
`
`1971-1984
`
`ACCOMPLISHMENTS
` Significant general management and operations experience.
` Recognized Industry leader in field sales and marketing.
` Proven track-record of leadership inspiring people to over-achieve.
` Created and built high performance teams and enhanced organizational structure.
` Consistently identified and developed hidden revenue opportunities into development and commercialized
`prescription products.
` Revitalized the most successful co-promotion arrangement in history of the pharmaceutical industry.
` Consistently applauded for achieving revenue and profit targets.
` Successfully managed small and large pharmaceutical organizations.
` Significant experience in integration of corporate acquisitions.
`
`
`APOTEX 1011, pg. 1
`
`

`
`
`
`
`HARRY C. BOGHIGIAN
`
`Page Two
`
`
`
`
`
`
`
`
`
`
`
`PBN PHARMA LLC, Chicago, IL
`President
`Research & Development Company focused on the marketing, licensing and divestiture of patented prescription
`and over-the-counter healthcare products covering a wide range of therapeutic areas PBN has a number of
`patented and patent pending products in various stages of development. Therapeutic areas include skin care, pain
`management and drug delivery systems. PBN introduced its first product in 2011 and a second in 2013.
`
`PHARMA CONSULTANTS LLC, Randolph, NJ
`President
`Specializing in developing and consulting on strategies and tactics for prescription, OTC, and healthcare related
`products. Custom work servicing advertising agencies, biotech, pharmaceutical and health related companies and
`expert reports for international law firms on behalf of their clients.
`
`ROCHE PHARMA, INC., Nutley, NJ
`Vice President Business Operations
`Profit and Loss responsibility for Business Operations representing Eastern half of United States with revenues in
`excess of $1 billion and 55% of corporate revenues. Managed a $130 million operating budget and refined
`execution of product strategies and tactics. Established expectations for hiring, managing, training and personal
`development of a 900 member field sales organization located within 10 regional business unit offices. Served as
`a member of the Business Operating Group, Business Strategic Forum, Strategic Alignment Steering Committee,
`Business Planning Process Committee and SB / Roche Steering Committee, Transformation 2000 Task Force.
` Driving force in Sales Force Transformation 2000 Project resulting in record productivity for managers and
`representatives.
` Recognized outpatient opportunities for prescribing of Rocephin IV and IM in Michigan, New York and Ohio
`resulting in three million dollars in incremental revenue and basis for national strategy to be implemented
`fourth quarter 2001.
` Achieved record levels in new prescription growth with Xenical (42.5%) and Tamiflu (74.6%) by
`implementing strategy of high frequency call activity and diverse programs on a limited target audience.
` Created Business Development Specialist to focus on non-traditional business customers capitalizing on
`untapped markets.
` Established enhanced focus on customer service with representative and account managers, resulting in
`several million dollars in incremental revenue.
` Developed and promoted three Business Unit Directors to Vice President.
`
`Vice President U.S. Marketing
`Corporate officer with total responsibility for re-building and reenergizing the marketing department, development
`of market strategies, 5 year revenue plans, and consulting with President and CEO on status of pharmaceutical
`business. Responsible for $2.3 billion portfolio of products. Sales increased 20% annually.
` Reorganized and staffed Marketing Intelligence, Career Training and Development, Sales Administration,
`Marketing, Promotion and Communications Department.
` Created and staffed first New Product Development & Planning, Consumer Marketing Leadership Center,
`Strategic Product Life Extension Group and Promotional Budget Management Departments.
` Directed hiring 60 high-grade individuals within 18-month period resulting in a First Class fully resourced
`Marketing Department totaling 270 full time and 45 full time contract employees in print department.
` Developed and implemented innovative strategies which delayed generic competition of Ticlid for 18 months
`representing an incremental $175 million in revenues.
` Created Marketing Operating Committee that successfully oversaw day-to-day operations of product
`marketing teams and service departments resulting in greater efficiencies and program synergies.
` Created and implemented extensive communication program and vision of “Becoming the Most Formidable
`Marketing Department in the Industry.”
`
`
`
`APOTEX 1011, pg. 2
`
`

`
`
`
`
`HARRY C. BOGHIGIAN
`
`Page Three
` Supervised the development of standards for numerous job functions related to budget and brand-lifecycle
`management.
` Developed comprehensive five-year revenue plans and strategies for major brands and presented them to
`Chairman and CEO.
` Successfully launched Posicor, Tasmar, Versed Syrup, Rocephin AOM, and Xenical (then the third most
`successful launch in pharmaceutical history). Oversaw Tamiflu launch plans.
` Supervised operating budget in excess of $50 million and promotional budgets of over $343 million resulting
`in a $12 million savings the first year and a $22 million savings in second year.
` Primary Care revenues grew 20% annually in ’97 and ’98 closing revenue gap of $250 million due to Posicor
`withdrawal from market and delay in Xenical introduction.
` Developed strategies and tactics, which slowed generic erosion of products off patent and provided $10.5+
`million in incremental revenues.
` Directed development of Klonopin to Zydis Drug Delivery System - launching 4Q 2001. Estimate first
`twelve months revenue at $55 million.
`
`
`Vice President – Southern Business Operations
`One of four senior executives that created and executed a new pharmaceutical business model for U.S.
`pharmaceutical business. Successful achievement of aggressive revenue and profit targets.
` Successfully launched five new products in 12 months and achieved revenue targets of $1.3 billion, a 16%
`increase.
`
`Installed and staffed twenty business unit offices across U.S.
` Created and implemented job descriptions, performance expectations and standards for entire pharmaceutical
`business operations group.
` Convinced senior management to add 56 incremental representatives in seven southern states with net return
`of $3 to 1. Became model for national expansion.
`
`
`HOFFMANN-LA ROCHE, Toronto, Canada
`Sr. Vice President and General Manager Roche Pharmaceuticals Canada
`General manager of pharmaceutical business responsible for sales, marketing, regulatory affairs, new business
`development, medical, professional services, federal and provincial government affairs, pricing, health economics,
`contracting, revenue growth, business expenses and profit and loss. Sales increased 82%.
` Hired new head of marketing and sales and reorganized management team.
` Created and chaired Marketing Board, a body of five department heads responsible for success of
`pharmaceutical business.
` Oversaw development of strategies and tactics resulting in successful launch of Mobiflex, Inhibace and
`Mannerix.
`
`Increased Rocephin sales 25% by hiring health economist and instituting a contracting program for hospitals.
` Successfully increased overall sales 82%.
`
`Integrated Syntex Pharmaceutical into Roche Organization resulting in a new company budget of $225
`million and reorganized sales force.
`
`
`HOFFMANN-LA ROCHE, Basel, Switzerland
`Group Director & Global Business Representative
`Responsible for revenue forecasts strategies and tactic of marketed and developmental compounds in
`cardiovascular, metabolic, gastrointestinal, central nervous system and oral anti-infectives.
`
` 
`
` Responsibility for development worldwide Xenical lifecycle forecast and US market development plans.
` Convinced global R&D to spend additional $9.5 million in two additional arms of the phase three studies of
`Xenical resulting in an incremental $50 million.
`
`
`
`APOTEX 1011, pg. 3
`
`

`
`
` HARRY C. BOGHIGIAN
`
` Page Four
`
`
`
` Revitalized the Roche/Glaxo co-promotion arrangement for Zantac and Ceftin. The most successful co –
`promotion arrangement in pharmaceutical history.
`
`
`
`
`
`
`
`ROCHE LABS, Nutley, NJ
`Product Director
`Developed strategic plans for marketed products and new brands in gastroenterology, cardiology, infectious
`disease, and CNS.
` Coordinated clinical development for Roche/Glaxo co-promotion of Zantac and Ceftin.
` Spearheaded successful physician and pharmacy educational symposia that ran across the country for three
`years.
` Responsible for long-term revenue projections and evaluating licensing and acquisition candidates.
`
`Regional Sales Director
` Directed 120 sales representatives with responsibility for 11 products and $215 million annual sales.
` Controlled an operating budget of $8 million.
`
`Manager, Market Research
` Directed a team of analysts to uncover opportunities, strategies and messages for existing and new
`prescription brands.
`
`
`HOFFMANN-LA ROCHE, Nutley, NJ
`Division Sales Manager, West Coast Florida
` Managed twelve sales representative covering gulf coast of Florida.
` Launched Rocephin (the #1 injectable antibiotic).
`
`Sales Representative, MA, NH & ME
` A consistent record of exceeding sales quotas. Received President’s Achievement Award four times. Highest
`company sales award.
` Responsible for selling pharmaceuticals, educational training materials (ROCOM) and clinical laboratory
`services. (RCL)
` Sold clinical laboratory services to physicians and hospitals. Established first clinical laboratory drawing
`station in New England.
`
`EDUCATION
`Bachelor of Science, Whittemore School of Business, University of New Hampshire
`
`Post Graduate Courses
`Executive Business Program
`Insead, European Institute of Business Administration, Fontainebleau Cedex, France
`
`Rising To Leadership Challenge
`London Business School, London England
`
`Type II Diabetes in the 90’s
`Harvard Medical School, Cambridge, Massachusetts
`
`Executive Leadership Program
`IMD, Lausanne, Switzerland
`
`
`
`APOTEX 1011, pg. 4
`
`

`
`
`
`HARRY C. BOGHIGIAN
`Page Five
`
`Leading Organizational Change & Renewal
`Harvard Business School, Cambridge, Massachusetts
`
`Pharmacology and Pharmacodynamics of CNS Acting Drugs
`University of Rochester Medical School, Rochester, New York
`
`Infections and Treatments of the Nineties
`Baylor College of Medicine, Houston, Texas
`
`Pharmaceutical Marketing
`Dartmouth College, Tuck School of Business, Hanover, New Hampshire
`
`
`
`
`
`
`
`PROFESSIONAL ASSOCIATIONS
`Healthcare Marketing Council, International Executive Guild
` UNH Whittemore School of Business & Economics Judge for Paul J. Holloway Business Plan Competition
` Chemist Club
`
`
`
` ADVISORY BOARDS
`
` University New Hampshire Alumni
`
`
`
`
`
`
`
`APOTEX 1011, pg. 5
`
`

`
`
`
`HARRY C. BOGHIGIAN
`
`Appendix: 1
`
`Trial Testimony in the Last Four Years:
`
`Pronova Biopharma Norge AS, Plaintiffs, v. Teva Pharmaceuticals USA, Inc. C.A. No.
`
`09-286-SLR-MPT; Apotex Corp., and Apotex Inc. C.A. No. 09-304-SLR-MPT; Par
`
`Pharmaceutical, Inc., and Par Pharmaceutical Companies, Inc., C.A. No. 09-305-SLR-
`
`MPT; Defendants, United States District Court for the District of Delaware. (April 6,
`
`2011)
`
`
`
`AstraZeneca Pharmaceuticals LP and AstraZeneca UK Limited, Plaintiffs v. Mylan
`
`Pharmaceuticals Inc. and Mylan Inc., Defendants, C.A. No. 10-cv-05519 (JAP) (TJB),
`
`C.A. No. 11-cv-2483 (JAP) (TJB, United States District Court For the District of New
`
`Jersey, October 13, 2011)
`
`
`
`Endo Pharmaceuticals Inc., Teikoku Pharma USA, Inc. and Teikoku Seiyaku., Ltd.,
`
`Plaintiffs, v. Watson Laboratories, Inc., Defendants, United States District Court For the
`
`District of Delaware, Civil Action No. 10-138 (GMS), February 9, 2012
`
`Schering Corporation, Plaintiffs vs Apotex, Inc. and Apotex Corp. Defendants, United
`
`States District Court for the District of New Jersey, Case No. 09-6373 (PGS) (TJB)
`
`(April 16, 2012)
`
`
`
`Ortho-McNeil-Janssen Pharmaceuticals, Inc. et al. v. Lupin Pharmaceuticals, Inc. and
`
`Lupin Ltd,. Civil Action No. 08-5103, United States District Court for the District of New
`
`Jersey (June 5, 2012)
`
`
`7 Tudor Place
`
`
`
`Randolph, New Jersey 07869
`
`
`
`
`973-476-6591
`
`
`APOTEX 1011, pg. 6
`
`

`
`
`
`HARRY C. BOGHIGIAN
`
`Appendix: 2
`
`Allergan, Inc. and Duke University, Plaintiffs v. Apotex Inc. and Apotex Corp., Sandoz,
`
`Inc., and Hi-Tech Pharmacal Co., Inc., Defendants Case, No. 1:10-CV-681, 1:11-CV-
`
`298, CV1:11-CV-650, United States District Court For the Middle District of North
`
`Carolina, November 20, 2012
`
`
`
`Cadence Pharmaceuticals, Inc. and SCR Pharmatop Plaintiffs v. Paddock Laboratories,
`
`Inc.; Perrigo Company, Exela Pharma Sciences, LLC; Exela Pharmsci, Inc.; And Exela
`
`Holdings, Inc., Defendants; Case No. 11-733-LPS, United States District Court for the
`
`District Court of Delaware, July 9, 2013
`
`
`
`Gilead Sciences, Inc. and Emory University, Plaintiffs v. Teva Pharmaceuticals USA,
`
`INC. and Teva Pharmaceutical Industries Ltd., Defendants, United States District Court,
`
`Southern District of New York, Case No. 08-CV-10838 (RJS), October 3, 2013
`
`
`
`Par Pharmaceutical, Inc. and Alkermes Pharma Ireland Ltd. Plaintiffs v. TWI
`
`Pharmaceuticals, Inc. Defendant, United States District Court For The District Of
`
`Maryland, Civil Action No. 11 CV2466, October 15, 2013
`
`
`
`Prometheus Laboratories Inc., Plaintiff v. Roxane laboratories, Inc., et al, Defendants
`
`United States District Court For The, District Of New Jersey, Civil Action Nos. 11-230,
`
`11-1241 (FSH)(PS), February 11, 2014.
`
`
`
`7 Tudor Place
`
`Randolph, New Jersey 07869
`
`973-476-6591
`
`
`
`
`
`
`APOTEX 1011, pg. 7
`
`

`
`
`
`HARRY C. BOGHIGIAN
`
`Appendix: 3
`
`Deposition Testimony in the Last Four Years:
`
`Pronova Biopharma Norge AS plaintiff v. Apotex Corp, TEVA Pharmaceuticals USA,
`
`Inc., Par Pharmaceuticals, Inc.; United States District Court for the District of
`
`Delaware,Civ. No. 09-304-SLR-MPT, Civ. No. 09-286-SLR-MPT, Civ. No. 09-305-
`
`SLR-MPT, (February 10, 2011)
`
`
`
`Bayer Schering Pharma AG & Bayer Healthcare Pharmaceuticals Inc., plaintiffs v.
`
`Lupin Limited and Lupin Pharmaceuticals, Inc., defendants, Civil Case No. 2:10-cv-
`
`0166-KJD-RJJ, United District Court for The District of Nevada (April 27, 2011).
`
`
`
`Sunovion Pharmaceuticals Inc., Plaintiff v. TEVA Pharmaceuticals USA, Inc. et al.,
`
`Defendant, United States District Court For The District Of New Jersey, Civil Action
`
`No.09-1302 (DMC)(MF), (May 18, 2011)
`
`
`
`Alcon Research, LTD., Plaintiffs v. Barr Laboratories, Inc., and Par Pharmaceutical,
`
`Inc., Defendants, Untied States District Court for the District of Delaware, C.A. No. 09-
`
`318 LDD, (May 26, 2011)
`
`
`
`Merck & Co., Inc., and Merck Sharp & Dohme Corp., Plaintiffs v. Sandoz, Inc.
`
`Defendant, C.A. NOS. 2:10-cv-01625, 2:10-02308-SRC-PS, United States District Court
`
`of New Jersey, (July 1, 2011)
`
`
`
`7 Tudor Place
`
`Randolph, New Jersey 07869
`
`973-476-6591
`
`
`
`
`
`
`APOTEX 1011, pg. 8
`
`

`
`
`
`HARRY C. BOGHIGIAN
`
`Appendix: 4
`
`AstraZeneca Pharmaceuticals LP and AstraZeneca UK Limited, Plaintiffs v. Mylan
`
`Pharmaceuticals Inc. and Mylan Inc., Defendants, C.A. No. 10-cv-05519 (JAP)(TJB),
`
`C.A. No. 11-cv-2483 (JAP)(TJB, United States District Court For the District of New
`
`Jersey, (July 19, 2011)
`
`
`
`Bone Care International LLC and Genzyme Corporation, Plaintiffs v. Anchen
`
`Pharmaceuticals, Inc., Mylan Pharmaceuticals, Inc. Sandoz, Inc., Untied States District
`
`Court for the District of Delaware, C.A. No. 09-285 (GMS)(consolidated), (August 19,
`
`2011).
`
`
`
`Endo Pharmaceuticals Inc., Teikoku Pharma USA, Inc. and Teikoku Seiyaku., Ltd.,
`
`Plaintiffs, v. Watson Laboratories, Inc., Defendants, United States District Court For the
`
`District of Delaware, Civil Action No. 10-138 (GMS), (October 26, 2011)
`
`
`
`Pfizer Inc., Pharmacia Corp., Pharmacia & Upjohn Company, Pharmacia & UpJohn
`
`Company LLC, C.P. Pharmaceuticals International, C.V., Plaintiffs v. Teva Parenteral
`
`Medicines, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries
`
`LTD, United States District Court For the District of Delaware, C.A. NO: 10-37 GMS,
`
`(November 2, 2011)
`
`
`
`Schering Corporation, Plaintiffs v. Apotex, Inc. and Apotex Corp. Defendants, United
`
`States District Court for the District of New Jersey, Case No. 09-6373 (PGS) (TJB),
`
`(December 13, 2011)
`7 Tudor Place
`
`
`
`Randolph, New Jersey 07869
`
`973-476-6591
`
`
`
`
`APOTEX 1011, pg. 9
`
`

`
`HARRY C. BOGHIGIAN
`
`Appendix: 5
`
`
`
`
`
`Pfizer Inc., Pharmacia &Upjohn Company LLC and Pfizer Health AB, Plaintiffs v. Impax
`
`Laboratories, Inc., and Mylan Inc. and Mylan Pharmaceuticals, Inc., United States
`
`District For the District of New Jersey, Civil Action No- CV-2137 (DMC)(JAD)
`
`Civil Action No. 10-CV-3246 (DMC)(JAD), Civil Action No. 10-CV-3250 (DMC)(JAD)
`
`(June 19, 2012)
`
`
`
`Allergan Inc. and Duke University, Plaintiffs v. Apotex Inc. and Apotex Corp, Case
`
`No.1:10-cv-681, Sandoz, Inc., Case No. 1:11-cv-298, Hi-Tech Pharmacal Co., Inc.
`
`Defendants, United States District Court for the Middle District of North Carolina,
`
`(July 17, 2012)
`
`
`
`GlaxoSmithKline (f/k/a SmithKlineBeecham Corporation), Plaintiff-Counterclaim
`
`Defendant, v. Anchen Pharmaceuticals, Inc., et al., (Banner Pharmacaps Inc. Roxane
`
`Laboratories, Inc., Watson Laboratories, Inc., Mylan Inc., Impax Laboratories Inc.),
`
`Defendants- Counterclaim Plaintiffs, United District Court for the District of Delaware,
`
`Civil Action No.11-cv-46 (RGA) (MPT) (consolidated) (August 3, 2012)
`
`
`
`Gilead Sciences, Inc. and Emory University, Plaintiffs v. Teva Pharmaceuticals USA,
`
`INC. and Teva Pharmaceutical Industries Ltd., Defendants, United States District Court,
`
`Southern District of New York, Case No. 08-CV-10838 (RJS) ( August 24, 2012)
`
`
`
`7 Tudor Place
`
`Randolph, New Jersey 07869
`
`973-476-6591
`
`
`
`
`
`
`APOTEX 1011, pg. 10
`
`

`
`
`
`HARRY C. BOGHIGIAN
`
`Appendix: 6
`
`Purdue Pharma, L.P., The P.F. Laboratories, Inc., Purdue Pharmaceutical L.P., and
`
`Rhodes Technologies, Plaintiffs v. Ranbaxy, Inc., Ranbaxy Pharmaceuticals, Inc.,
`
`Ranbaxy Laboratories LTD., Actavis Elizabeth LLC, Defendants, United States District
`
`Court For the Southern District Of New York, Number 1:11-CV-07104 (August 31,
`
`2012)
`
`
`
`Prometheus Laboratories Inc., Plaintiff v. Roxane Laboratories Inc., et al., Defendants,
`
`United States District Court For The District Of New Jersey, Civil Action No. 11-0230
`
`(FSH) (PS), Civil Action No. 11-1241 (FSH) (PS) (October 10, 2012)
`
`
`
`Par Pharmaceutical, Inc. and Alkermes Pharma Ireland Ltd. Plaintiffs v. TWI
`
`Pharmaceuticals, Inc. Defendant, United States District Court For The District Of
`
`Maryland, Civil Action No. 11 CV2466 (March 7, 2013)
`
`
`
`Cadence Pharmaceuticals, Inc. and SCR Pharmatop Plaintiffs, v. Paddock Laboratories,
`
`Inc.; Perrigo Company, Exela Pharma Sciences, LLC; Exela Pharmsci, Inc.; And Exela
`
`Holdings, Inc., Defendants; Case No. 11-733-LPS, United States District Court for the
`
`District Court of Delaware (June 22, 2013)
`
`
`
`7 Tudor Place
`
`Randolph, New Jersey 07869
`
`973-476-6591
`
`
`
`
`
`
`APOTEX 1011, pg. 11